A Rational Designed Novel Bispecific Antibody for the Treatment of GBM

Epidermal growth factor receptor variant III (EGFRvIII) is highly and specifically expressed in a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for GBM. Recently, bispecific antibodies (BsAbs) have shown exciting clinical benefits in cancer immunotherapy. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Rui, Zhou, Yuexian, Han, Lei, Pan, Zhidi, Chen, Jie, Zong, Huifang, Bian, Yanlin, Jiang, Hua, Zhang, Baohong, Zhu, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230177/
https://www.ncbi.nlm.nih.gov/pubmed/34204931
http://dx.doi.org/10.3390/biomedicines9060640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230177/
https://www.ncbi.nlm.nih.gov/pubmed/34204931
http://dx.doi.org/10.3390/biomedicines9060640

Ejemplares similares